These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22652851)

  • 1. Global burden of visual impairment and blindness.
    Bourne R; Price H; Stevens G;
    Arch Ophthalmol; 2012 May; 130(5):645-7. PubMed ID: 22652851
    [No Abstract]   [Full Text] [Related]  

  • 2. Prevalence and burden of self-reported blindness, low vision, and visual impairment in the French community: a nationwide survey.
    Brézin AP; Lafuma A; Fagnani F; Mesbah M; Berdeaux G
    Arch Ophthalmol; 2005 Aug; 123(8):1117-24. PubMed ID: 16087847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Simple Method for Estimating the Economic Cost of Productivity Loss Due to Blindness and Moderate to Severe Visual Impairment.
    Eckert KA; Carter MJ; Lansingh VC; Wilson DA; Furtado JM; Frick KD; Resnikoff S
    Ophthalmic Epidemiol; 2015; 22(5):349-55. PubMed ID: 26395661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global prevalence of vision impairment and blindness: magnitude and temporal trends, 1990-2010.
    Stevens GA; White RA; Flaxman SR; Price H; Jonas JB; Keeffe J; Leasher J; Naidoo K; Pesudovs K; Resnikoff S; Taylor H; Bourne RRA;
    Ophthalmology; 2013 Dec; 120(12):2377-2384. PubMed ID: 23850093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prevalence of Eye Injury in the United States, Estimates from a Meta-Analysis.
    Swain T; McGwin G
    Ophthalmic Epidemiol; 2020 Jun; 27(3):186-193. PubMed ID: 31847651
    [No Abstract]   [Full Text] [Related]  

  • 6. Nonmedical economic consequences attributable to visual impairment: a nation-wide approach in France.
    Lafuma A; Brezin A; Fagnani F; Mimaud V; Mesbah M; Berdeaux G
    Eur J Health Econ; 2006 Sep; 7(3):158-64. PubMed ID: 16850334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic impact of visual impairment and blindness in the United States.
    Frick KD; Gower EW; Kempen JH; Wolff JL
    Arch Ophthalmol; 2007 Apr; 125(4):544-50. PubMed ID: 17420375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What the comprehensive economics of blindness and visual impairment can help us understand.
    Frick KD
    Indian J Ophthalmol; 2012; 60(5):406-10. PubMed ID: 22944750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic cost of visual impairment in Japan.
    Roberts CB; Hiratsuka Y; Yamada M; Pezzullo ML; Yates K; Takano S; Miyake K; Taylor HR
    Arch Ophthalmol; 2010 Jun; 128(6):766-71. PubMed ID: 20547955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical care cost of Medicare/Medicaid beneficiaries with vision loss.
    Morse AR; Pyenson BS
    Ophthalmic Epidemiol; 2009; 16(1):50-7. PubMed ID: 19191182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis.
    Jonas JB; Bourne RR; White RA; Flaxman SR; Keeffe J; Leasher J; Naidoo K; Pesudovs K; Price H; Wong TY; Resnikoff S; Taylor HR;
    Am J Ophthalmol; 2014 Oct; 158(4):808-15. PubMed ID: 24973605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The National Eye Survey of Trinidad and Tobago (NESTT): Rationale, Objectives and Methodology.
    Braithwaite T; Verlander NQ; Bartholomew D; Bridgemohan P; McNally K; Roach A; Sharma S; Singh D; Pesudovs K; Teelucksingh S; Carrington C; Ramsewak S; Bourne R;
    Ophthalmic Epidemiol; 2017 Apr; 24(2):116-129. PubMed ID: 28107088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Socioeconomics With Prevalence of Visual Impairment and Blindness.
    Wang W; Yan W; Müller A; Keel S; He M
    JAMA Ophthalmol; 2017 Dec; 135(12):1295-1302. PubMed ID: 29049446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2002 global update of available data on visual impairment: a compilation of population-based prevalence studies.
    Pascolini D; Mariotti SP; Pokharel GP; Pararajasegaram R; Etya'ale D; Négrel AD; Resnikoff S
    Ophthalmic Epidemiol; 2004 Apr; 11(2):67-115. PubMed ID: 15255026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimating the burden and economic impact of trachomatous visual loss.
    Frick KD; Basilion EV; Hanson CL; Colchero MA
    Ophthalmic Epidemiol; 2003 Apr; 10(2):121-32. PubMed ID: 12660860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global estimates of visual impairment: 2010.
    Pascolini D; Mariotti SP
    Br J Ophthalmol; 2012 May; 96(5):614-8. PubMed ID: 22133988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost of care for people with impaired vision in Australia.
    Keeffe JE; Chou SL; Lamoureux EL
    Arch Ophthalmol; 2009 Oct; 127(10):1377-81. PubMed ID: 19822857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vision impairment and major causes of vision loss impacts on vision-specific functioning independent of socioeconomic factors.
    Chiang PP; Zheng Y; Wong TY; Lamoureux EL
    Ophthalmology; 2013 Feb; 120(2):415-22. PubMed ID: 23149127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blindness and low vision in The Netherlands from 2000 to 2020-modeling as a tool for focused intervention.
    Limburg H; Keunen JE
    Ophthalmic Epidemiol; 2009; 16(6):362-9. PubMed ID: 19995201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and causes of blindness and visual impairment among school children in south-western Nigeria.
    Ajaiyeoba AI; Isawumi MA; Adeoye AO; Oluleye TS
    Int Ophthalmol; 2005; 26(4-5):121-5. PubMed ID: 17200795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.